# FDA Scientists Oppose HHS Plan to Ease Access to Unproven Peptides Scientific staff resist administration efforts to bypass safety regulations for injectable wellness substances. - **Source:** [ABC News: Technology](http://abcnews.com) - **Published:** 2026-10-28 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/5247afc1-d706-4753-a80f-acf106071a3b ## Internal FDA Scientific Opposition FDA scientific staff members have formally opposed a Department of Health and Human Services plan to loosen restrictions on unproven peptide drugs. These experts argue the policy undermines the agency's mission to keep untested health products off the market. Staffers had limited input during the initial drafting of this controversial regulatory document. ## Shift in Regulatory Strategy The administration initially sought to classify peptides like BPC-157 as safe for compounding pharmacies. After FDA officials warned of significant safety risks, the approach shifted to a non-enforcement policy. This directive instructs the FDA to stop taking action against specialty pharmacies that sell these substances, effectively bypassing standard rigorous vetting processes. ## Safety Risks of Peptides Peptides such as BPC-157 and TB-500 are currently promoted for muscle building and injury healing. However, the FDA previously added these substances to a list of prohibited compounded drugs in 2023. Risks identified by agency scientists include potential tumor growth, kidney damage, and severe allergic reactions among users of these injectable products. ## Compounding Industry Context Compounding pharmacies have evolved from a niche sector into a multibillion-dollar industry providing customized medications. The FDA increased its focus on this sector following a 2012 fungal meningitis outbreak linked to contaminated injections. Federal law grants HHS authority over drug regulations, though the FDA typically manages the technical oversight of these entities. ## Gray Market Challenges Health Secretary Robert F. Kennedy Jr. advocates for easier access, citing the prevalence of unregulated products imported from China. Many consumers currently bypass doctors and pharmacies, purchasing vials online labeled for research use only. This gray market activity complicates the FDA’s ability to monitor substance quality and ensure consumer safety standards. ## Technical Guardrails and Compromise Despite their opposition, FDA staffers provided technical assistance to include safety guardrails in the final HHS plan. These measures require pharmacies to source ingredients from FDA-regulated factories and collect data on side effects. Compounders must also verify the chemical identity of peptides to mitigate risks, though the core safety concerns remain. ## White House Regulatory Review The proposed policy recently underwent final regulatory review at the White House. By directing the FDA to refrain from enforcement rather than changing official regulations, the administration avoids a direct confrontation with agency scientists. This tactical shift allows the policy to proceed toward publication despite ongoing internal resistance from career FDA staff. ## Implications for Agency Authority This development highlights a rare instance of HHS taking the lead on specific drug compounding policies over the FDA. The tension underscores the conflict between political initiatives and established scientific vetting procedures. The outcome will determine whether the FDA maintains its traditional role as the primary gatekeeper for pharmaceutical safety standards. ## Sources covering this story - https://abcnews.com/Technology/wireStory/fda-scientists-opposed-trump-administrations-effort-ease-peptides-137644299 — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._